01:41 AM EDT, 09/29/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) launched a biosimilar drug substance production center in Lendava, Slovenia. The new facility supports the Swiss drugmaker's Bio100 strategy, under which it aims to build a portfolio of more than 100 biosimilars by 2040, according to a Tuesday release. The facility will use smart automation and process analytical technology and employ over 300 people.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.